PCSK9 and metabolic syndrome: These findings support the hypothesis that higher levels and/or activity of plasma PCSK9 increase the levels of circulating LDL-C and TC, suggesting that long-term lowering of PCSK9 might be beneficial in reducing the incidence of CAD, and hence PCSK9 is an attractive target for treatment of dyslipidemia [22]–[24].